Amgen has entered into a six-year sourcing and supply agreement with DaVita, Inc., continuing its long-term relationship with DaVita focused on serving dialysis patients.

 Amgen will supply DaVita with EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) to meet a specified annual percentage of DaVita's requirements for erythropoiesis-stimulating agents used in providing dialysis services in the U.S. and Puerto Rico. The percentage varies during the term of the new agreement from Jan. 6, 2017, through Dec. 31, 2022, but in each year is at least 90%. The new agreement will replace the sourcing and supply agreement dated Nov. 15, 2011, that would have expired on Dec. 31, 2018